HGF/c-Met raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-03-02. Anything still debated is marked as such rather than presented as settled.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
| Property | Value | Notes |
|---|---|---|
| Chemical name | N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Common full name in research literature. |
| Class | Synthetic peptide | Modified angiotensin IV analog. |
| Related compound | Angiotensin IV | Parent peptide fragment. |
| Proposed target | HGF/c-Met pathway | Described as an HGF mimetic; not fully confirmed. |
| Development status | Preclinical research | No widely approved clinical use. |
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
JRT, also known as isotryptamine-LSD, is a serotonin receptor modulator, psychoplastogen, and serotonergic psychedelic related to lysergic acid diethylamide (LSD). It is the analogue of LSD in which the embedded tryptamine structure within the ergoline ring system of LSD has been replaced with an isotryptamine structure. The drug acts as a non-selective serotonin receptor modulator, including as a partial agonist of the serotonin 5-HT2A receptor and as an agonist or antagonist of various other serotonin receptors. The drug has psychedelic-like, psychoplastogenic, antipsychotic-like, antidepressant-like, and pro-cognitive effects in animals and preclinical studies, whilst lacking apparent pro-psychotic-like effects. It has significant but reduced psychedelic-like effects compared to LSD in animals. The drug is a racemic mixture of (+)- and (–)- enantiomers, with (+)-JRT being the active and employed form. JRT was first described in the scientific literature by 2022 and was described in greater detail in 2025. It was developed by David E. Olson and colleagues in association with Delix Therapeutics. The drug is being investigated as a possible treatment for schizophrenia.
Early in embryonic development, the embryo has three germ layers and abuts a yolk sac. During the second week of development, the embryo grows and begins to surround and envelop portions of this sac. The enveloped portions form the basis for the adult gastrointestinal tract. Sections of this foregut begin to differentiate into the organs of the gastrointestinal tract, such as the esophagus, stomach, and intestines. During the fourth week of development, the stomach rotates. The stomach, originally lying in the midline of the embryo, rotates so that its body is on the left. This rotation also affects the part of the gastrointestinal tube immediately below the stomach, which will go on to become the duodenum. By the end of the fourth week, the developing duodenum begins to spout a small outpouching on its right side, the hepatic diverticulum, which will go on to become the biliary tree. Just below this is a second outpouching, known as the cystic diverticulum, that will eventually develop into the gallbladder.
The largest concentration of Southern Rhodesian troops in the Italian Campaign of 1943–45 was the group of about 1,400, mainly from the Southern Rhodesian Reconnaissance Regiment, spread across the South African 6th Armoured Division. The 11th South African Armoured Brigade, one of the 6th Division's two main components, was made up of Prince Alfred's Guard, the Pretoria Regiment (Princess Alice's Own) and the Special Service Battalion, each of which had a Rhodesian squadron of Sherman tanks. The other, the 12th South African Motorised Brigade, comprised infantry—the Witwatersrand Rifles, the Natal Carbineers and the Cape Town Highlanders, the last of which had a large Rhodesian contingent. There were also two Rhodesian artillery batteries—the original Rhodesian Anti-Tank Battery and a newer unit of Rhodesian field gunners. After a year's training in Egypt, the division sailed to Italy in April 1944, landing towards the end of the month at Taranto. No. 237 Squadron, now flying Spitfires, rebased to Corsica the same month to operate over Italy and southern France. The 6th Division moved north-west from Taranto to take its place as part of the Eighth Army alongside the US Fifth Army. It took part in the fourth and final Allied assault of the Battle of Monte Cassino in the second and third weeks of May 1944, helping to force the Germans out, and thereafter advanced north-west up the Liri valley to join the Allied forces at Anzio and advance onwards to Rome.
=== Stem-wind, pin-set movements === Much like the lever-set movements, these pocket watches had a small pin or knob next to the watch-stem that had to be depressed before turning the crown to set the time and releasing the pin when the correct time had been set. This style of watch is occasionally referred to as "nail set", as the set button must be pressed using a fingernail.
In a lecture on 14 September 2007, Dietmar von Reeken described the emergence of a "Lower Saxony consciousness" in the 19th century, the geographical basis of which was used to invent a territorial construct: the resulting local heritage societies (Heimatvereine) and their associated magazines routinely used the terms "Lower Saxony" or "Lower Saxon" in their names. At the end of the 1920s in the context of discussions about a reform of the Reich, and promoted by the expanding local heritage movement (Heimatbewegung), a 25-year conflict started between "Lower Saxony" and "Westphalia". The supporters of this dispute were administrative officials and politicians, but regionally focussed scientists of various disciplines were supposed to have fuelled the arguments. In the 1930s, a real Lower Saxony did not yet exist, but there were a plethora of institutions that would have called themselves "Lower Saxon". The motives and arguments in the disputes between "Lower Saxony" and "Westphalia" were very similar on both sides: economic interests, political aims, cultural interests and historical aspects.
Sources: en.wikipedia.org
There are relatively simple tests for radon gas. In some countries these tests are methodically done in areas of known systematic hazards. Radon detection devices are commercially available. Digital radon detectors provide ongoing measurements giving both daily, weekly, short-term and long-term average readouts via a digital display. Short-term radon test devices used for initial screening purposes are inexpensive, in some cases free. There are important protocols for taking short-term radon tests and it is imperative that they be strictly followed. The kit includes a collector that the user hangs in the lowest habitable floor of the house for two to seven days. The user then sends the collector to a laboratory for analysis. Long term kits, taking collections for up to one year or more, are also available. An open-land test kit can test radon emissions from the land before construction begins. Radon concentrations can vary daily, and accurate radon exposure estimates require long-term average radon measurements in the spaces where an individual spends a significant amount of time. Radon levels fluctuate naturally, due to factors like transient weather conditions, so an initial test might not be an accurate assessment of a home's average radon level. Radon levels are at a maximum during the coolest part of the day when pressure differentials are greatest. Therefore, a high result (over 4 pCi/L) justifies repeating the test before undertaking more expensive abatement projects. Measurements between 4 and 10 pCi/L warrant a long-term radon test.
Tin (50Sn) is the element with the greatest number of naturally abundant isotopes, 10. Seven, 114-120Sn, are theoretically stable, while the remaining three, 112Sn, 122Sn, and 124Sn, are potentially radioactive to double beta decay, but no decay has been observed. This is generally attributed to the fact that 50 is a "magic number" of protons. In addition, 32 unstable tin isotopes are known, including tin-100 (100Sn) and tin-132 (132Sn), which are both "doubly magic". The longest-lived of these is tin-126 (126Sn), with a half-life about 230,000 years; with all others less than a year and the majority under 20 minutes. The number of known metastable states is very large, including a long series of low-lying states in odd isotopes from 117 on, which gives two nuclides with a longer life than any ground-state radioisotope other than 126: 121mSn, half-life 43.9 years, and 119mSn, half-life 293.1 days.
=== 1963-1967 === In 1963, the Los Angeles Rams acquired Rosey Grier from the New York Giants to play right defensive tackle. Grier joined Lamar Lundy (right defensive end), and future Hall of Famers Merlin Olsen (left defensive tackle) and Deacon Jones (left defensive end) on the team's starting defensive line. In 1964, the Rams' publicity office began using the "Fearsome Foursome" name to describe the team's defensive line, reportedly following the Chargers example. It was the Rams' Fearsome Foursome, however, that became the standard by which future teams' defensive lines were measured. Hall of Fame linebacker, and one of the NFL's greatest defensive players, Dick Butkus called them "the most dominant line in football history." The Associated Press’s obituary of Jones called the Rams line unblockable at times, and reported descriptions of Jones as the paradigm for all the great defensive ends that followed, an “icon among icons” and the “‘greatest defensive end of modern football’”. Grier missed the 1967 season with a ruptured Achilles tendon (and retired before the 1968 season). In September 1967, the Rams traded three high draft choices, including the Rams No. 1 pick in the 1968 draft, to the Detroit Lions for the Lions' Fearsome Four tackle Roger Brown to replace Grier. Brown joined the Rams' Fearsome Foursome, where he played with Jones, Olsen and Lundy from 1967 to 1969. Brown made the Pro Bowl in 1967 (his sixth consecutive appearance). In 2018, USA Today Sportswriter Jim Reineking rated the 1967 Rams line as the greatest ever.
== Practical uses == While at first the chemical garden may appear to be primarily a toy, some serious work has been done on the subject. For instance, this chemistry is related to the setting of Portland cement, the formation of hydrothermal vents, and the corrosion of steel surfaces on which insoluble tubes can be formed. The nature of the growth of the insoluble silicate tubes formed within chemical gardens is also useful in understanding classes of related behavior seen in fluids separated by membranes. In various ways, the growth of the silicate tubes resembles the growth of spikes or blobs of ice extruded above the freezing surface of still water, the patterns formed by drying gum as it drips from wounds in trees such as Eucalyptus, and the way molten wax forms twig-like growths, either dripping from a candle, or floating up through cool water. The fundamental principles governing their self-assembly and membrane dynamics have been extensively leveraged across multiple scientific disciplines, including biomedicine (e.g., engineering cellular scaffolds and bone substitute materials), and astrobiology (e.g., modeling prebiotic compartmentalization and the emergence of life in hydrothermal vent environments). Chemobrionic materials have also been investigated as active layers in memristive devices for neuromorphic computing.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.
No, dihexa is a synthetic compound derived from the structure of angiotensin IV. Angiotensin IV occurs naturally, but dihexa has modifications that change its properties. It is not a standard dietary component.
The main hypothesis is that dihexa interacts with the hepatocyte growth factor system, possibly through c-Met signaling. This interaction may influence synaptogenesis and neuronal plasticity. The exact molecular target remains an active area of study.
Published human trials are lacking. Most evidence comes from laboratory and animal studies. Therefore, human benefits and risks are not established.